Here's what to expect when Johnson & Johnson reports earnings before the bell

Here's what to expect when Johnson & Johnson reports earnings before the bell

Earnings 17 Jul, 2018

Emile Wamsteker | Bloomberg | Getty Images

Johnson & Johnson is expected to report second-quarter earnings Tuesday before the bell.

Here's what Wall Street analysts polled by Thomson Reuters expect:

Earnings: $2.07 per shareRevenue: $20.39 billion

Pharmaceuticals, particularly cancer drugs, have fueled J&J’s success.

Meanwhile, the company has continued pruning its medical device business, including selling its LifeScan diabetes unit to private-equity firm Platinum Equity for $2.1 billion. It received a binding offer last month from Fortive Corp. for its Advanced Sterilization Products business for $2.8 billion.

J&J’s consumer segment has lagged, with baby care weighing on sales. In May, the company unveiled its revamped product line, which it plans to roll out to stores in August.

A Missouri jury last week ordered J&J to pay $4.69 billion to 22 women who claim the company's talc-based products, including its baby powder, contained asbestos and allegedly caused them to develop ovarian cancer. J&J has vowed to fight the verdict.

(Original source)